Anti-SARS-CoV-2 Monoclonal Antibodies
Last Updated: August 04, 2021
Table A. SARS-CoV-2 Variants of Concern and Interest and Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies
|WHO Label||Pango Lineage||CDC Variant Class||Notable Mutations||Bamlanivimab Plus Etesevimab||Casirivimab Plus Imdevimab||Sotrovimab|
|In Vitro Susceptibilitya||Activityb||In Vitro Susceptibilitya||Activityb||In Vitro Susceptibilitya||Activityb|
|Alpha||B.1.1.7||VoC||N501Y||No change||Active||No change||Active||No change||Active|
|Beta||B.1.351||VoC||K417N, E484K, N501Y||Marked change||Unlikely to be active||No changec||Active||No change||Active|
|Gamma||P.1||VoC||K417T, E484K, N501Y||Marked change||Unlikely to be active||No changec||Active||No change||Active|
|Delta||B.1.617.2||VoC||L452R||Modest changed||Likely to be active||No change||Active||No change||Active|
|Epsilon||B.1.429/B.1.427||VoI||L452R||Modest changed||Likely to be active||No change||Active||No change||Active|
|Iota||B.1.526||VoI||E484K||Modest changed||Likely to be active||No changec||Active||No change||Active|
a Based on the fold reduction in susceptibility reported in the FDA EUAs.5-7
b Anticipated clinical activity against the variant, based on in vitro studies.
c Marked change for casirivimab and no change for imdevimab. The combination of casirivimab plus imdevimab appears to retain activity.
d Modest change for the combination of bamlanivimab and etesevimab, although the clinical implications of this finding are not fully known.
Key: CDC = Centers for Disease Control and Prevention; VoC = variant of concern; VoI = variant of interest; WHO = World Health Organization